Payment overview · 2025
General Payments
$54.50
3 reported records · 2 companies
Healthcare provider profile · identity verified
Adam J. Leaderman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1407808892
Verified facts
What the public records show
CMS Open Payments records show Adam J. Leaderman, MD received $54.50 in general payments during 2025 across 3 reported records.
Amgen Inc. accounted for 59.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.59 | 59.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.91 | 40.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $54.50 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.59 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1091 | 306 |
| Amlodipine Besylate | Amlodipine Besylate | 582 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 431 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 97 |
| Losartan Potassium | Losartan Potassium | 367 | 102 |
| Lisinopril | Lisinopril | 344 | 94 |
| Zolpidem Tartrate | Zolpidem Tartrate | 262 | 70 |
| Ezetimibe | Ezetimibe | 258 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 72 |
| Metformin Hcl Er | Metformin Hcl | 215 | 62 |
| Omeprazole | Omeprazole | 197 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 49 |
| Mounjaro | Tirzepatide | 170 | 23 |
| Famotidine | Famotidine | 162 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 40 |
| Allopurinol | Allopurinol | 152 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 148 | 42 |
| Gabapentin | Gabapentin | 147 | 46 |
| Alprazolam | Alprazolam | 128 | 41 |
| Trazodone Hcl | Trazodone Hcl | 124 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 41 |
| Sertraline Hcl | Sertraline Hcl | 105 | 27 |
| Alendronate Sodium | Alendronate Sodium | 103 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 24 |
| Carvedilol | Carvedilol | 93 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 93 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 23 |
| Clonazepam | Clonazepam | 83 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 79 | 26 |
| Ozempic | Semaglutide | 79 | 11 |
| Simvastatin | Simvastatin | 79 | 23 |
| Synthroid | Levothyroxine Sodium | 78 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 73 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 19 |
| Meloxicam | Meloxicam | 72 | 27 |
| Jardiance | Empagliflozin | 71 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 21 |
| Telmisartan | Telmisartan | 68 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 18 |
| Montelukast Sodium | Montelukast Sodium | 67 | 15 |
| Lorazepam | Lorazepam | 65 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 65 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 14 |
| Potassium Chloride | Potassium Chloride | 57 | 21 |
| Bupropion Xl | Bupropion Hcl | 56 | 17 |
| Azithromycin | Azithromycin | 53 | 50 |
| Eliquis | Apixaban | 51 | 13 |
| Finasteride | Finasteride | 51 | 14 |
| Furosemide | Furosemide | 49 | 16 |
| Prednisone | Prednisone | 48 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Tramadol Hcl | Tramadol Hcl | 47 | 13 |
| Doxepin Hcl | Doxepin Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Celecoxib | Celecoxib | 42 | 15 |
| Spironolactone | Spironolactone | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Prolia | Denosumab | 35 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 18 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 11 |
| Metformin Hcl | Metformin Hcl | 31 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Estradiol | Estradiol | 28 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Methylprednisolone | Methylprednisolone | 22 | 18 |
| Testosterone | Testosterone | 22 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ritalin | Methylphenidate Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 15 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 14 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $54.50 · 3 records | Amgen Inc. | EVENITY, General - Pain Management | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error